Recombinant human interferon- in the treatment of condylomata acuminata

Abstract

The number of clinic consultations for condylomata acuminata (genital warts) has increased substantially during the last 30 years. Most infections produce benign lesions but a few types may be associated with cervical and penile cancers. Interferons (IFN) have shown antiviral properties to these infections and IFN-beta in particular has demonstrated a specific cytopathic effect in humans. A total of 124 patients with condylomata acuminata, the majority of whom had failed previous therapy, were treated intralesionally with either recombinant human interferon-beta la (r-hIFN-beta-1a) or placebo. Up to 6 lesions were treated in each patient, and injections were made 3 times per week for a total of 9 injections. The patients were then followed up for 3 months. Efficacy assessments at all time points (day 19, week 6 and month 3) showed a clear advantage for the r-hIFN-beta-1a interferon-beta treatment. Patients receiving r-hIFN-beta-1a showed a greater proportion of treatment success in terms of the complete or partial reduction (at least 50%) of the total area of the treated lesions. The treatment was also well tolerated. Headache, flu-like symptoms and asthenia were more common in patients receiving r-hIFN-beta-1a, but these adverse events were generally mild in severity and rarely led to patient withdrawal. It was concluded that r-hIFN-beta-1a has good efficacy in condylomata acuminata, and therefore presents a useful therapeutic alternative in this hard-to-treat condition.

Interferon (IFN)-β Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN-α

“…21,22 Although IFN-␣ and IFN-␤ have been considered to share many of their biological activities, mainly because of the binding to the same receptor, evidence exists indicating possible differences in their in vitro and in vivo effects, in terms of antiproliferative, [23][24][25][26][27][28][29] antiviral, 30,31 signal transduction, [32][33][34][35] immunomodulatory, 36 -39 anti-invasive, 40,41 and anti-angiogenic properties. 42,43 Although IFN-␤ as a single agent has been successfully used in the therapy of chronic hepatitis C, 44 some benign proliferative diseases, 45 and most recently in relapsing multiple sclerosis, 46 IFN-␣ is the most widely used cytokine in the therapy of certain human malignancies, 21 and its antitumor activity is generally assumed to be superior to that of IFN-␤, even though comparative clinical evaluations in cancer patients have not been performed.…”

Anogenital siğiller: İnsan papilloma virüsü, klinik bulguları ve tedavi stratejileri üzerine bir güncelleme

“…Cervical cancer: High-risk HPV subtypes (HPV 16 and HPV 18) are the causes of approximately 70% of invasive cervical cancer and it is estimated that 500,000 cases of cervical cancer occur each year worldwide. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] A study of paraffin-embedded samples of 10,575 cases of cervical cancer demonstrated that the most common HPV types were 16,18,31,33,35,45,52, and 58; HPV types 16 and 18 represented 71% of the cases overall. 25 Other anogenital cancers: Vaginal, vulvar, penile and anal cancers and their precancerous precursors such as vulvar intraepithelial neoplasia (IN), penile IN, anal IN are other associated neoplasies.…”

“…Experience with these agents is more limited than for other medical therapies. [49][50][51][52][53] Imiquimod: Imiquimod is a toll-like receptor 7 agonist, which acts as a positive immune response modifier, and stimulates local cytokine induction. Two formulations are available, Aldara (5% imiquimod) and Zyclara (3.75% imiquimod).…”

Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy

“…Complete response rates for IFN treatment groups generally varied from 28% 191 to 100% 195 with 9 out of 16 studies surveyed reporting complete response rates between 40% and 60%. 186,188,190,192,193,[196][197][198][199] Furthermore, warts treated with intralesional IFN may continue to resolve for days to weeks after the treatment. 187 While most intralesional IFN studies focus on IFNa treatments, IFNf3 has been studied and demonstrated results comparable to IFNa in most trials.…”

“…187 While most intralesional IFN studies focus on IFNa treatments, IFNf3 has been studied and demonstrated results comparable to IFNa in most trials. [194][195][196][197][198][199] Systemic IFN therapy of genital warts has been studied with IFNa, IFNf3, and IFN')'.200-216 These studies reported highly variable results. IFNa demonstrated complete response rates in IFN treatment groups ranging from 18%209 to 71%207 with 6 out of9 studies (with more than 2 participants) reporting complete response rates between 20% and 50%.…”